Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Go back to Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
(NASDAQ: JAGX) Delayed: 2.25 --0 (-0%)
Previous Close $2.25    52 Week High $4.60 
Open $2.25    52 Week Low $0.81 
Day High $2.25    P/E N/A 
Day Low $2.25    EPS $0.00 
Volume 1,499